dulaglutide biosimilar
China Approves Boyouping® (BA5101), the World’s First Dulaglutide Biosimilar and First Domestic Product
China’s NMPA approved Boyouping® (BA5101), the world’s first dulaglutide biosimilar and first domestic product for type 2 diabetes. Developed by Boan Biotech and commercialized by Shanghai Pharma, Boyouping® matches Eli Lilly’s Trulicity® in efficacy and safety, with plans for global expansion.